Ahmad Ramahi, MD
Rheumatology · Roswell, NMNPI 1457872350
Payments from drug & device makers
What this record shows
This record is dominated by grants: $34,583 of the $35,322 with a category attached, or 97.9%. Pfizer accounts for 97.9% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2020 at $34,583 and has fallen 99.2% since, to $267 in 2025. Among rheumatology clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 32 payments — averaging $1103.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$35K
- Amgen$200
- Novartis$75
- AstraZeneca$63
- Regeneron Healthcare Solutions, Inc.$54
- Daiichi Sankyo Inc.$42
- plus $305 from 13 others
What the payments were for
- Grants$34,58398%
- Food & beverage$5952%
- Education$1450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 1 | $34,583 |
| Amgen | 5 | $200 |
| Novartis | 3 | $75 |
| AstraZeneca(2 entities) | 3 | $63 |
| Regeneron Healthcare Solutions, Inc. | 2 | $54 |
| Daiichi Sankyo Inc. | 2 | $42 |
| AbbVie | 2 | $39 |
| Sobi, Inc | 2 | $38 |
| Inspire Medical Systems, Inc. | 1 | $35 |
| Coherus Oncology, Inc. | 2 | $32 |
| Merck | 1 | $24 |
| Gilead | 1 | $21 |
| Incyte Corporation | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Immunocore Limited | 1 | $16 |
| Axonics, Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $15 |
| Tersera Therapeutics LLC | 1 | $14 |
How this compares
$35,322 in reported general payments places this provider in the 95th percentile of 44 rheumatology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 151 | $1,165,463 |
| Orencia ClickjectAbatacept | 58 | $334,743 |
| Enbrel SureclickEtanercept | 45 | $332,351 |
| OrenciaAbatacept | 40 | $238,745 |
| Humira(Cf) PenAdalimumab | 24 | $175,489 |
| KevzaraSarilumab | 36 | $163,201 |
| HumiraAdalimumab | 19 | $152,355 |
| Actemra ActpenTocilizumab | 33 | $145,576 |
| Yuflyma(Cf) Autoinject (2 Pck)Adalimumab-Aaty | 16 | $142,431 |
| Enbrel MiniEtanercept | 14 | $106,941 |
| RinvoqUpadacitinib | 16 | $102,788 |
| XeljanzTofacitinib Citrate | 16 | $85,714 |
| ActemraTocilizumab | 16 | $84,945 |
| Leflunomide | 163 | $6,799 |
| Mycophenolate Mofetil | 43 | $5,984 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira, Rinvoq | $39 | $255,14335 claims |
| PfizerXeljanz | $34,583 | $85,71416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 44 rheumatology providers in New Mexico.
Other rheumatology in Roswell
- Zain Ul AbideenRoswell$5K
- Hillary NortonSanta Fe$1.9M
- Adrian Michaella Mesilla$16K
- Wilmer SibbittAlbuquerque$9K
- Arthur SnyderLas Cruces$9K
- Leroy PachecoAlbuquerque$8K
- Albert RizzoliAlbuquerque$7K
- Susan BarrettSanta Fe$7K
- Jayashree SinhaClovis$7K
- Scott StoernerAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.